GROWTH
Top line stable.
+11.5% YoY versus +9.8% prior. Analysts model +9.3% next FY.
+11.5%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
2 of 2 legendary models say BUY MDLN.
What would legendary investors pay for MDLN?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
+11.5% YoY versus +9.8% prior. Analysts model +9.3% next FY.
+11.5%Net margin 4.1% versus 4.7% prior (−0.6pp). Operating 7.8%.
4.1%P/E 27.8x — 9% below the 5y median of 30.6x. Forward 23.7x hints at EPS expansion next year.
27.8xBottom line: MDLN is rated BUY by 1 of 2 legendary models, with 1 holding and 0 flagging it overvalued, but earns a C sector grade (50/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
The Question
Concerns — Medline Inc.'s 8.6% ROE is below sector median.
Financial story
Concerns — Medline Inc.'s 8.6% ROE and 1.74 debt-to-equity warrant a closer look at the underlying business.
MDLN is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
2 of 2 legendary investor models rate MDLN a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Average fair value across qualifying models: $88. See the per-investor fair-value table in the valuation tab.
MDLN trades at 29.9x earnings. Sector context and per-investor signals are in the valuation tab.
MDLN and NTRA differ on P/E, ROE, and revenue growth. See the full MDLN vs NTRA compare matrix.
Buffett and Lynch evaluate MDLN against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
How does MDLN compare?
See exactly where MDLN ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingMDLN sits at #54 in Healthcare with a C grade (50/100).
